Abstract
Objectives Several lines of emerging pharmacological and epidemiological evidence imply that overall risks related to COVID-19 may be reduced by green tea catechins. Therefore, it may be expected that: (i) higher green tea consumption is associated with lower COVID-19 morbidity and/or mortality; (ii) countries with higher per/capita green tea consumption would be less affected by COVID-19. The aim of this study was to assess the second possibility.
Study design This was a cross-sectional study.
Methods Among countries with at least 3 million population (n=134), countries with relatively high (above 150 g) per/capita green tea consumption have been tentatively identified (n=21); (ii) normalized to population values of COVID-19 cases (morbidity) and deaths (mortality) for groups of countries with high and low per/capita green tea consumption were compared.
Results Striking differences in COVID-19 morbidity (and mortality) between groups of countries with higher and lower green tea consumption. The differences were still observed after the adjustment for the onset of the disease. Besides, preliminary analysis using multiple linear regression approach suggests that the associations are present at the level of individual countries.
Conclusion Evidence supporting the idea that green tea constituents could reduce overall risks related to COVID-19 has been obtained. The results are promising and are in line with emerging evidence from other studies including pharmacological ones. Nevertheless, because of limitations of this study the idea still should be considered as a hypothesis requiring further assessment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been followed. All necessary patient/participant consent has been obtained (this was an analysis of publicly available data).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data derived from public domain resources
